22-January-2026
Corporate News
 
Dr Reddy's profit down 14% on low Lenalidomide US sales
22-Jan-2026

Pharma major Dr Reddy’s Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm’s revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.

News Source:- https://www.rediff.com/business/report/dr-reddys-profit-down-14-on-low-lenalidomide-us-sales/20260122.htm
 
 
 

Notes:
1. Copyright and ownership of all content from IMC and other IMC sites belongs to IMC except third-party resources
2. Copyright, intellectual property right, ownership or responsibility of error of other content belong to respective sources
3. Please do not reply to this mail

For suggestions and feedback click here.

Disclaimer:
IMC is not responsible for any kind of loss arising due to the information. You are receiving this newsletter because you have subscribed to this service. To unsubscribe click here.
Head Office : IMC Bldg., IMC Marg, Churchgate, Mumbai - 400 020 India  |   Tel : 91-22-22046633  |   Fax : 91-22-22048508 / 22838281
E-Mail : imc@imcnet.org  |   Website : www.imcnet.org